glp-1 fda approved for pcos 💊New pill gets approval, and has fewer restrictions on how it's used💊 Wegovy vs Mounjaro: How GLP-1

In a Phase 2 clinical trial published in 2023 in the New England Journal of Medicine (Jastreboff et al.), participants receiving the highest dose of retatrutide lost up to approximately 24% of their body weight over 48 weeks a notably greater reduction than observed with currently approved agents

More comprehensive insight into the effects of GLP-1 RAs on gastrointestinal and central nervous system functions is required

These concerns are valid and worth exploring

Patients who need reliable 12- to 13-hour coverage without an afternoon booster dose may find lisdexamfetamine's duration profile worth the cost difference

Weight Fluctuation: Why It Happens and What You Can Do